158 results
Page 5 of 8
SC TO-T/A
EX-99
tgwnk0a3bqoy7gk xk
19 Jan 12
Third party tender offer statement (amended)
12:00am
SC TO-T
EX-99
im3ekvksda
13 Jan 12
Third party tender offer statement
12:00am
SC TO-T
EX-99
hc0kehzkw0
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
4j8dr3nvv9jape
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am
8-K
EX-99.1
utz2su2ofkkdr e8k
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-99.1
8uz6th9itmh0
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
2lsb44z
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
i5qxgx 532b8
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
SC TO-T/A
EX-99
8vg5w88lff
29 Sep 10
Third party tender offer statement (amended)
12:00am
SC TO-T/A
EX-99
soe5s
13 Sep 10
Third party tender offer statement (amended)
12:00am